Navigation Links
Arizona companies team up, providing quick development of cancer drugs
Date:1/26/2011

FLAGSTAFF, Ariz. Jan. 26, 2011 TGen Drug Development (TD2) and Flagship Biosciences today announced a strategic alliance that should help speed new drugs safely into human testing and quickly benefit cancer patients.

TD2, based in Scottsdale, Ariz., provides drug development firms with expertise in moving promising laboratory discoveries through the pre-clinical, clinical and regulatory approval steps of getting new drugs to patients as quickly and safely as possible.

Flagship Biosciences, based in Flagstaff, Ariz., will greatly assist in this process by providing high-throughput, multiplexed immunohistochemistry expertise to support preclinical drug development and human clinical trials.

"Flagship's technology will significantly accelerate our ability to identify biomarkers that could help researchers predict which drug compounds will work best on specific patient cancers," said TD2 President Dr. Stephen Gately.

And because Flagship's affiliated laboratories are certified by the U.S. Food and Drug Administration, under the 1988 federal Clinical Laboratory Improvement Amendments (CLIA) law, these findings can be translated directly into clinical trials, where they can benefit patients as quickly as possible.

Specifically, Flagship provides computerized histopathology, the microscopic study of diseased tissue, which is a critical part of anatomical pathology and key to the accurate diagnosis of cancer and other diseases from sample tissues. Flagship also provides deep expertise in measuring epithelialmesenchymal transition (EMT), the process in which tumor cells become highly invasive, migratory and resistance to therapy.

"The local tumor environment is key to understanding efficacy and toxicity of oncology compounds in both preclinical and clinical trials, and EMT is central to understanding stromal involvement and fibrosis in cancer patients," said Dr. Gately. "Working with Flagship Biosciences brings a wealth of pathology knowledge in pharmaceutical product development, experience in difficult histology analysis."

When combined with TD2's integrated suite of molecular analysis tools designed to reduce the uncertainty in the drug development process, the partnership with Flagship will provide emerging drug companies with the promise of quickly and safely getting their discoveries to market.

"TD2 is the world-leader in novel approaches to oncology and oncology clinical trials," said Dr. David Young, President of Flagship Biosciences. "It is exciting to be partnering with TD2, and combining our quantitative pathology with TD2's oncology and molecular tumor profiling expertise. TD2's leadership in novel approaches to oncology clinical trials is an exciting match for digital pathology techniques and the promise of quantitative and virtual pathology analysis of patients and tumor response."

"This partnership is a further demonstration of the emerging regional strength of Arizona for biotech product development," said Dr. Robert Kellar, a board member of Flagship Biosciences. "Arizona is a unique resource for pharma, biotech, and device clients looking for the rapid application of new technology in development and clinical trials."


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Experts converge at Arizona State University for first preventive cancer vaccine conference
2. ASU professor named top in state of Arizona
3. NIH funds center at Arizona State to battle infectious diseases
4. University of Arizona-led group awarded $9.9 million to develop super rice
5. New research will unravel Arizonas prehistoric puzzle of the Hohokam ceramic industry
6. First Arizona Strides for Life event nets $25,000 for TGen research
7. TGen provides Arizona with $77 million in annual economic impact
8. DOE funds bio-inspired solar fuel center at Arizona State
9. Reportlinker Adds Biomarkers - technologies, markets and companies
10. TGen Drug Development accompanies GPEC to BayBio2010
11. Study highlights sustainable footprint of chemical companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):
(Date:5/24/2017)... , May 23, 2017 As Ebola resurfaces ... with four deaths and 20 suspected cases now reported, a ... the PubMed database, showed a correlation between the 2014 and ... Replikin counts rose sharply in 2012-13, which preceded the 2014 ... in the Ebola gene Replikin counts in 2014-15, which again ...
(Date:5/23/2017)... (PRWEB) , ... May 23, ... ... offer an unlimited source of human cardiovascular cells for research and the ... methods makes it possible to generate large numbers of cardiomyocytes (hPSC-CMs). Due ...
(Date:5/23/2017)... Washington, USA (PRWEB) , ... May 22, 2017 ... ... SPIE Optics and Photonics 2017 in San Diego, California, this August will ... reality, solar fuels, and autonomous vehicles. , SPIE Optics and Photonics, the largest ...
(Date:5/23/2017)... ... 23, 2017 , ... Kathy Goin is joining myClin ... brings years of expertise in establishing and leading clinical operations at Sponsors including ... occupational therapist, through a variety of leadership roles in Clinical Operations, to her ...
Breaking Biology Technology: